Sorafenib Market Report by Type (Patented Drugs, Generic Drugs), Application (Kidney Cancer, Liver Cancer, Thyroid Cancer), and Region 2024-2032

Sorafenib Market Report by Type (Patented Drugs, Generic Drugs), Application (Kidney Cancer, Liver Cancer, Thyroid Cancer), and Region 2024-2032

Report Format: PDF+Excel | Report ID: SR112024A9356
Buy Now

Market Overview: 

The global sorafenib market size reached US$ 1,143.3 Million in 2023. Looking forward, IMARC Group expects the market to reach US$ 1,245.3 Million by 2032. The increasing incidence of cancer, rising awareness among the masses regarding early cancer detection and treatments, and the recent development of biomarker-guided treatment represent some of the key factors driving the market.

Report Attribute
 Key Statistics 
Base Year
Forecast Years
Historical Years
Market Size in 2023
US$ 1,143.3 Million
Market Forecast in 2032
US$ 1,245.3 Million

Sorafenib refers to an oral multi-kinase inhibitor drug that is used in the targeted treatment for carcinoma. It exhibits a dual mechanism of action by blocking the rapidly accelerated fibrosarcoma (RAF) kinase pathway, which prevents the spread of cancer and reduces tumor growth. Sorafenib is widely used in targeted and combination therapies to treat hepatocellular carcinoma (HCC), renal cell carcinoma (RCC), differentiated thyroid carcinoma, and non-small cell lung cancer. It is a highly lipophilic compound that easily spreads across tissues, deeply penetrates cell membranes, and reaches its target more effectively. Sorafenib also provides anti-proliferative and anti-angiogenic properties, which aid in disrupting cancer cell progression, inhibit the growth of tumor blood vessels, and restrict access to essential resources required for tumor proliferation.

Sorafenib Market Trends:

The increasing incidence of cancer across the globe due to genetics, sedentary lifestyle, and unhealthy eating habits is one of the primary factors providing an impetus to the market growth. Sorafenib is a highly effective medication used to treat liver, kidney, and thyroid cancer by reducing tumor angiogenesis and increasing apoptosis in cancer cells. In addition to this, the growing demand for novel therapies that are more effective and offer minimum side effects is acting as another growth-inducing factor. Furthermore, the rising awareness among the masses regarding early cancer detection and treatments to improve outcomes, prolong survival, and reduce future complications is strengthening the market growth. Additionally, the recent development of biomarker-guided treatment, which involves identifying specific biomarkers that can predict a patient’s response to sorafenib, thus improving treatment effectiveness and enhancing overall survival rate, is positively influencing the market growth. Apart from this, the utilization of a nanoparticle-based drug delivery system, which improves sorafenib stability and bioavailability, is supporting the market growth. Besides this, the introduction of generic variants of sorafenib that are cost-effective and easily accessible to patients from different income groups is propelling the market growth. Moreover, the implementation of supportive policies by several governments to spread awareness regarding cancer and its treatments and provide access to high-quality healthcare facilities is contributing to the market growth. Other factors, including rising geriatric populations, growing healthcare expenditure, extensive research and development (R&D) activities, and increasing approvals for new drugs, are anticipated to drive the market growth.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each segment of the global sorafenib market, along with forecasts at the global, regional, and country levels from 2024-2032. Our report has categorized the market based on type and application.

Type Insights:

  • Patented Drugs
  • Generic Drugs

The report has provided a detailed breakup and analysis of the sorafenib market based on the type. This includes patented and generic drugs. According to the report, patented drugs represented the largest segment.

Application Insights:

  • Kidney Cancer
  • Liver Cancer
  • Thyroid Cancer

A detailed breakup and analysis of the sorafenib market based on the application has also been provided in the report. This includes kidney cancer, liver cancer, and thyroid cancer. According to the report, kidney cancer accounted for the largest market share.

Regional Insights:

  • North America
    • United States
    • Canada
  • Europe
    • Germany
    • France
    • United Kingdom
    • Italy
    • Spain
    • Others
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Others
  • Latin America
    • Brazil
    • Mexico
    • Others
  • Middle East and Africa

The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Europe (Germany, France, the United Kingdom, Italy, Spain, and others); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America was the largest market for sorafenib. Some of the factors driving the North America sorafenib market included the rising prevalence of cancer, the implementation of supportive government policies, and enhanced focus of research and development (R&D) activities.

Competitive Landscape:

The report has also provided a comprehensive analysis of the competitive landscape in the global sorafenib market. Competitive analysis such as market structure, market share by key players, player positioning, top winning strategies, competitive dashboard, and company evaluation quadrant has been covered in the report. Also, detailed profiles of all major companies have been provided. Some of the companies covered include Bayer AG, Cipla Limited, Hetero Healthcare Limited, NATCO Pharma Limited, etc. Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.

Report Coverage:

Report Features Details
Base Year of the Analysis 2023
Historical Period 2018-2023
Forecast Period 2024-2032
Units US$ Million
Scope of the Report Exploration of Historical and Forecast Trends, Industry Catalysts and Challenges, Segment-Wise Historical and Predictive Market Assessment: 
  • Type
  • Application
  • Region 
Types Covered Patented Drugs, Generic Drugs
Applications Covered Kidney Cancer, Liver Cancer, Thyroid Cancer
Regions Covered  Asia Pacific, Europe, North America, Latin America, Middle East and Africa
Countries Covered United States, Canada, Germany, France, United Kingdom, Italy, Spain, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico
Companies Covered Bayer AG, Cipla Limited, Hetero Healthcare Limited, NATCO Pharma Limited, etc.
Customization Scope 10% Free Customization
Report Price and Purchase Option Single User License: US$ 3899
Five User License: US$ 4899
Corporate License: US$ 5899
Post-Sale Analyst Support 10-12 Weeks
Delivery Format PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)

Key Questions Answered in This Report:

  • How has the global sorafenib market performed so far, and how will it perform in the coming years?
  • What are the drivers, restraints, and opportunities in the global sorafenib market?
  • What is the impact of each driver, restraint, and opportunity on the global sorafenib market?
  • What are the key regional markets?
  • Which countries represent the most attractive sorafenib market?
  • What is the breakup of the market based on the type?
  • Which is the most attractive type in the sorafenib market?
  • What is the breakup of the market based on the application?
  • Which is the most attractive application in the sorafenib market?
  • What is the competitive structure of the global sorafenib market?
  • Who are the key players/companies in the global sorafenib market?

Key Benefits for Stakeholders:

  • IMARC’s report offers a comprehensive quantitative analysis of various market segments, historical and current market trends, market forecasts, and dynamics of the sorafenib market from 2018-2032.
  • The research study provides the latest information on the market drivers, challenges, and opportunities in the global sorafenib market.
  • The study maps the leading, as well as the fastest-growing, regional markets. It further enables stakeholders to identify the key country-level markets within each region.
  • Porter's five forces analysis assist stakeholders in assessing the impact of new entrants, competitive rivalry, supplier power, buyer power, and the threat of substitution. It helps stakeholders to analyze the level of competition within the sorafenib industry and its attractiveness.
  • Competitive landscape allows stakeholders to understand their competitive environment and provides an insight into the current positions of key players in the market. 

Need more help?

  • Speak to our experienced analysts for insights on the current market scenarios.
  • Include additional segments and countries to customize the report as per your requirement.
  • Gain an unparalleled competitive advantage in your domain by understanding how to utilize the report and positively impacting your operations and revenue.
  • For further assistance, please connect with our analysts.
Sorafenib Market Report by Type (Patented Drugs, Generic Drugs), Application (Kidney Cancer, Liver Cancer, Thyroid Cancer), and Region 2024-2032
Purchase options

Benefits of Customization

Personalize this research

Triangulate with your data

Get data as per your format and definition

Gain a deeper dive into a specific application, geography, customer, or competitor

Any level of personalization

Get in Touch With Us

Phone: +1-631-791-1145


Phone: +91-120-433-0800


Phone: +44-753-714-6104


Client Testimonials

Aktive Services

IMARC made the whole process easy. Everyone I spoke with via email was polite, easy to deal with, kept their promises regarding delivery timelines and were solutions focused. From my first contact, I was grateful for the professionalism shown by the whole IMARC team. I recommend IMARC to all that need timely, affordable information and advice. My experience with IMARC was excellent and I can not fault it.

Read More
Greenfish S.A.

The IMARC team was very reactive and flexible with regard to our requests. A very good overall experience. We are happy with the work that IMARC has provided, very complete and detailed. It has contributed to our business needs and provided the market visibility that we required

Read More
Colruyt Group

We were very happy with the collaboration between IMARC and Colruyt. Not only were your prices competitive, IMARC was also pretty fast in understanding the scope and our needs for this project. Even though it was not an easy task, performing a market research during the COVID-19 pandemic, you were able to get us the necessary information we needed. The IMARC team was very easy to work with and they showed us that it would go the extra mile if we needed anything extra

Read More

Last project executed by your team was as per our expectations. We also would like to associate for more assignments this year. Kudos to your team.

Read More
Zee Media Corp. Ltd.

We would be happy to reach out to IMARC again, if we need Market Research/Consulting/Consumer Research or any associated service. Overall experience was good, and the data points were quite helpful.

Read More
Arabian Plastic Manufacturing Company Ltd.

The figures of market study were very close to our assumed figures. The presentation of the study was neat and easy to analyse. The requested details of the study were fulfilled. My overall experience with the IMARC Team was satisfactory.

Read More
Sumitomo Corporation

The overall cost of the services were within our expectations. I was happy to have good communications in a timely manner. It was a great and quick way to have the information I needed.

Read More
Hameln Rds

My questions and concerns were answered in a satisfied way. The costs of the services were within our expectations. My overall experience with the IMARC Team was very good.

Read More
Quality Consultants BV

I agree the report was timely delivered, meeting the key objectives of the engagement. We had some discussion on the contents, adjustments were made fast and accurate. The response time was minimum in each case. Very good. You have a satisfied customer.

Read More
TATA Advanced Systems Limited

We would be happy to reach out to IMARC for more market reports in the future. The response from the account sales manager was very good. I appreciate the timely follow ups and post purchase support from the team. My overall experience with IMARC was good.

Read More

IMARC was a good solution for the data points that we really needed and couldn't find elsewhere. The team was easy to work, quick to respond, and flexible to our customization requests.

Read More